

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1302)

VOLUNTARY ANNOUNCEMENT

**STRATEGIC COLLABORATION AGREEMENT
ENTERED INTO IN RELATION TO
INNOVATIVE SURGICAL ROBOTIC SOLUTION**

This announcement is made by LifeTech Scientific Corporation (the “**Company**”) on a voluntary basis to provide the shareholders and potential investors with updated information in relation to the latest business and new product development of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 2 April 2019, Lifetech Scientific (Shenzhen) Co., Ltd, a wholly controlled subsidiary of the Company, entered into a Strategic Collaboration Agreement with ABG Innovation-Quantum Limited, an investment holding company controlled by Ally Bridge Group who is a cross-border life science investment group (“**ABG**”) and Quantum Surgical SAS (“**Quantum Surgical**”), an innovative surgical robotics company registered in France, who is an industrial pioneer focused on R&D, design, manufacturing and servicing activities of a surgical robot platform for interventional oncology and its commercialization, to establish a joint venture in Guangdong, China (the “**JV**”) to focus on the R&D and commercialization of specified products (including Quantum Integrated Robotized Platform for International Oncology and next generation versions, etc.) (the “**Innovative Surgical Robot**”), particularly for liver cancer treatment in China. The Company believes it marks the Company’s entrance into the industry for cancer treatment in China of great market potential.

The Company shall become the majority shareholder of the JV and will be responsible for the setting up and operation of the JV as well as contributing its deep market know-how to help expedite the product approval and commercialization in

China. Quantum Surgical will be responsible for the product development, clinical studies and regulatory approval of Innovative Surgical Robot in the United States and Europe. After the launch of the Innovative Surgical Robot in the market, the JV will be granted (i) exclusive distribution rights of such products in China and other countries to be mutually agreed between Quantum Surgical and the Company for a period of five-years commencing on the approval of such products by the China National Medical Products Administration; and (ii) the first right to develop and localize its products in China.

Forming this JV in China will serve as a new model for sino-foreign collaboration in innovative medical technologies. It is expected that the Company's strong regulatory know-how and established commercialization infrastructure in China, coupled with Quantum Surgical's advanced technology and ABG's global industry network and capital markets enable the contemplated JV to accelerate the commercialization of the Surgical Robot Platform and benefit millions of cancer patients

The Company believes this is a win-win partnership, and it is a ground-breaking step achieved by the Company in investing in and partnering with global leading healthcare technology. The establishment of the JV, when it materialises, will mark a new milestone of the Company for strategic and operational partnership with global leading medical companies in China.

The Strategic Cooperation Agreement serves as a guiding document for the future cooperation of the parties by way of a contemplated JV. Details of the capital contribution to be made by the Company or other parties in the contemplated joint venture is subject to further negotiation and has not yet been finalized. Further announcement(s) will be made by the Company in accordance with the applicable requirements of the Listing Rules as and when appropriate.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
*Chairman, Chief Executive Officer
and Executive Director*

Hong Kong, 3 April 2019

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.